

Drug Utilization Review Board

(DUR Board)

Meeting – July 8, 2009 @ 6:00 p.m.

Oklahoma Health Care Authority

4545 N. Lincoln Suite 124

Oklahoma City, Oklahoma 73105

Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. June 10, 2009 DUR Minutes – Vote
 - B. June 11, 2009 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / MCAU Program – See Appendix B.**
 - A. Retrospective Drug Utilization Review for March 2009
 - B. Medication Coverage Activity Audit for June 2009
 - C. Help Desk Activity Audit for June 2009

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Anti-Migraine Products – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

6. **30 Day Notice to Apply Quantity Restrictions to Hydrocodone Products – See Appendix D.**
 - A. Utilization Review
 - B. Current Restrictions
 - C. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

- 7. 30 Day Notice to Prior Authorize Gelnique™ and Update of Bladder Control Products Product Based Prior Authorization Criteria – See Appendix E.**
 - A. Product Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Patel, Dr. Muchmore, Chairman

- 8. Utilization Review of Fibromyalgia Products – See Appendix F.**
 - A. Fibromyalgia Overview
 - B. Utilization Review
 - C. COP Recommendations
 - D. Product Summaries

Items to be presented by Dr. Chonlahan, Dr. Muchmore, Chairman

- 9. Utilization Review of Otic Antibiotics – See Appendix G.**
 - A. Diagnosis and Etiology
 - B. Treatment Options
 - C. Utilization Review
 - D. COP Recommendations

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

- 10. FDA and DEA Updates – See Appendix H.**

- 11. Future Business**
 - A. Proton Pump Inhibitors Annual Review
 - B. Anxiolytic Criteria Review
 - C. New Product Reviews
 - D. Annual Reviews

- 12. Adjournment**